Assessment of Anti-Helicobacter Pylori Eradication Regimens in Basrah Gastroenterology and Hepatology Hospital

Abstract

Background: For Helicobacter pylori eradication failures, levofloxacin-based therapy has been widely recommended. Objective: To find the most efficient H. pylori eradication treatment in Basrah. Method: The Basrah Gastroenterology and Hepatology Hospital conducted a prospective descriptive study from September to December 2022. Patients with dyspepsia who presented to the outpatient clinic were tested for H. pylori infection. The study included 66 patients who had a confirmed diagnosis of infection by either a H. pylori stool antigen test or a urea breath test. They were allocated to one of two eradication regimens at random: regimen A (omeprazole, levofloxacin, and amoxicillin) and regimen B (omeprazole, clarithromycin, and metronidazole). Patients were re-evaluated and tested for H. pylori infection after a 4-week follow-up period. Symptom relief and medication side effects were recorded. Results: Sixty-two patients were enrolled; the mean age was 34.97 years, with a range of 7 to 68 years. Thirty-six (58.1%) were female, while 26 (41.9%) were male. In the follow-up test, the majority of patients (85.5%) tested negative, representing the total eradication rate. When compared to regimen A, regimen B had a larger number of patients reporting side effects (29.1% vs. 9.7%). Regimen A demonstrated a significantly greater rate of effective eradication compared to regimen B. In regimen B, the percentage of patients who had no change in symptoms following therapy was larger (32.3%) than in regimen A (6.5%). Conclusion: A levofloxacin-based treatment (regimen A) is more effective in eradicating H. pylori infection than regimen B.